RecruitingPriority 4 · Lower priorityNCT07470996
T Cell Lymphoma -Stratified Therapy After Response to First-line Treatment-NR
Plain-language summary
This trial is evaluating Allogenic stem cell transplant (ASCT) and Salvage Therapy as a treatment for people newly diagnosed with T-cell lymphoma. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.
Who can join (key eligibility)
- Age 18 Years to 70 Years years
- Newly diagnosed, not yet treated
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Allogenic stem cell transplant (ASCT) (PROCEDURE): ASCT involves the infusion of stem cells collected from a donor (genetically similar, but not identical). | Salvage Therapy (PROCEDURE): This term encompasses a range of potential alternative regimens instead of allogeneic hematopoietic stem cell transplantation
- Drugs / treatments
- Allogenic stem cell transplant (ASCT), Salvage Therapy
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details